Total ERK1/2 Base Kit

Related Publications	Journal	Year

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. Spitzer, P., Scheib, H., Kamrowski-Kruck, H, Otto, M., Chiasserini, D., Parnetti, L., Herukka, S.K., Schuchhart, J., Wiltfang, J., Klafki, H.W.	International Journal of Alzheimer's Disease.	2011
Characterization of a murine keyhole limpet hemocyanin (KLH)-delayed-type hypersensitivity (DTH) model: role for p38 kinase. Engstrom, L., Pinzon-Ortiz, M.C., Li, Y., Chen, S.C., Kinsley, D., Nelissen, R., Fine, J.S., Mihara, K., Manfra, D.	Int Immunopharmacol.	2009
Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function. Singh, B.N., Hayes, G.R., Lucas, J.J., Sommer, U., Viseux, N., Mirgorodskaya, E., Trifonova, R.T., Sassi, R.R., Costello, C.E., Fichorova, R.N.	Glycoconj J.	2009
Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Grund, E.M., Kagan, D., Tran, C.A., Zeitvogel, A., Starzinski-Powitz, A., Nataraja, S., Palmer, S.S.	Mol Pharmacol.	2008
Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. Klafki, H.W., Lewczuk, P., Kamrowski-Kruck, H., Maler, J.M., Müller, K., Peters, O., Heuser, I., Jessen, F., Popp, J., Frölich, L., Wolf, S., Prinz, B., Luckhaus, C., Schröder, J., Pantel, J., Gertz, H.J., Kölsch, H., Müller, B.W., Esselmann, H., Bibl, M., Kornhuber, J., Wiltfang, J.	Alzheimers Dis.	2009
In Vivo and In Vitro Characterization of a First-in-Class Novel Azole Analog That Targets Pregnane X Receptor Activation. Venkatesh, M., Wang, H., Cayer, J., Leroux, M., Salvail, D., Das, B., Wrobel, J.E., Mani, S.	Mol Pharmacol.	2011
The FGFR D3 Domain Determines Receptor Selectivity For Fibroblast Growth Factor 21. Gupte, J., Yang, L., Wu, X., Weiszmann, J., Hecht, R., Lemon, B., Lindberg, R., Wang, Z., Li, Y.	J Mol Biol.	2011
Selective and potent raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Carnahan, J., Beltran, P.J., Babij, C., Le, Q., Rose, M.J., Vonderfecht, S., Kim, J.L., Smith, A.L., Nagapudi, K., Broome, M.A., Fernando, M., Kha, H., Belmontes, B., Radinsky, R., Kendall, R., Burgess, T.L.	Mol Cancer Ther.	2010
ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release. Hua, F., Henstock, P.V., Tang, B.	Int Immunopharmacol.	2010
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Wu, X., Ge, H., Lemon, B., Weiszmann, J., Gupte, J., Hawkins, N., Li, X., Tang, J., Lindberg, R., Li, Y.	Proc Natl Acad Sci USA.	2009
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models-Association with liver and adipose tissue effects. Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y.Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.C., Graham, M., Busby, J., Hecht, R., Li, Y.S., Li, Y., Lindberg, R.A., Véniant, M.M.	Am J Physiol Endocrinol Metab.	2009
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. Brake, R., Starnes, C., Lu, J., Chen, D., Yang, S., Radinsky, R., Borges, L.	Mol Cancer Res.	2008
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Dahut, W. L., Scripture, C., Posadas, E., Jain, L., Gulley, J. L., Arlen, P.M., Wright, J.J., Yu, Y., Cao L., Steinberg, S.M., Aragon-Ching, J.B., Venitz, J., Jones, E., Chen, C.C., Figg, W. D.	Clin Cancer Res.	2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Eccles, S.A., Massey, A., Raynaud, F.I., Sharp, S.Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., Aherne, W., Rowlands, M., Hayes, A., Martins, V., Urban, F., Boxall, K., Prodromou, C., Pearl, L., James, K., Matthews, T.P., Cheung, K.M., Kalusa, A., Jones, K., McDonald, E., Barril, X., Brough, P.A., Cansfield, J.E., Dymock, B., Drysdale, M.J., Finch, H., Howes, R., Hubbard, R.E., Surgenor, A., Webb, P., Wood, M., Wright, L., Workman, P.	Cancer Res.	2008
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Khakoo, A.Y., Pati, S., Anderson, S.A., Reid, W., Elshal, M.F., Rovira, I.I., Nguyen, A.T., Malide, D., Combs, C.A., Hall, G., Zhang, J., Raffeld, M., Rogers, T.B., Stetler-Stevenson, W., Frank, J.A., Reitz. M., Finkel, T.	J Exp Med.	2006
Transcriptional activation of inflammasome components by Libby amphibole and the role of iron. Shannahan JH, Ghio AJ, Schladweiler MC, Richards JH, Andrews D, Gavett SH, Kodavanti UP.	Inhal Toxicol.	2012
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Bielen A, Box G, Perryman L, Bjerke L, Popov S, Jamin Y, Jury A, Valenti M, Brandon Ade H, Martins V, Romanet V, Jeay S, Raynaud FI, Hofmann F, Robinson SP, Eccles SA, Jones C.	Proc Natl Acad Sci U S A.	2012
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. Sharma J, Lv H, Gallo JM.	J Pharm Sci.	2012
Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. Gurley SN, Abidi AH, Allison P, Guan P, Duntsch C, Robertson JH, Kosanke SD, Keir ST, Bigner DD, Elberger AJ, Moore BM 2nd.	J Neurooncol.	2012
Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes Hecht R, Li Y, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, Smith S, Spahr C, Tam L, Shen Z, Stanislaus S, Chinookoswong N, Lau Y, Sickmier A, Michaels ML, Boone T, Veniant MM, Xu J.	PLoS One	2012